Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleOncology

Hexokinase 2 Is Targetable for HK1-Negative, HK2-Positive Tumors from a Wide Variety of Tissues of Origin

Shili Xu, Arthur Catapang, Hanna M. Doh, Nicholas A. Bayley, Jason T. Lee, Daniel Braas, Thomas G. Graeber and Harvey R. Herschman
Journal of Nuclear Medicine February 2019, 60 (2) 212-217; DOI: https://doi.org/10.2967/jnumed.118.212365
Shili Xu
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur Catapang
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hanna M. Doh
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nicholas A. Bayley
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason T. Lee
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
2Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
3Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Braas
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
4UCLA Metabolomics Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas G. Graeber
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
2Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
3Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
4UCLA Metabolomics Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harvey R. Herschman
1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
2Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
3Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
5Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; and
6Molecular Biology Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 60 no. 2 212-217
DOI 
https://doi.org/10.2967/jnumed.118.212365
PubMed 
29880505

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication April 4, 2018
  • Accepted for publication May 31, 2018
  • Published online February 1, 2019.

Article Versions

  • previous version (June 7, 2018 - 08:01).
  • previous version (August 30, 2018 - 14:02).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2019 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Shili Xu1,
  2. Arthur Catapang1,
  3. Hanna M. Doh1,
  4. Nicholas A. Bayley1,
  5. Jason T. Lee1–3,
  6. Daniel Braas1,4,
  7. Thomas G. Graeber1–4 and
  8. Harvey R. Herschman1–35,6
  1. 1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  2. 2Crump Institute for Molecular Imaging, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  3. 3Jonsson Comprehensive Cancer Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  4. 4UCLA Metabolomics Center, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  5. 5Department of Biological Chemistry, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California; and
  6. 6Molecular Biology Institute, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California
  1. For correspondence or reprints contact: Harvey R. Herschman, 341 Boyer Hall, University of California Los Angeles, 611 Charles E. Young Dr. East, Los Angeles, CA, 90095. E-mail: hherschman{at}mednet.ucla.edu
View Full Text

Statistics from Altmetric.com

Cited By...

  • 17 Citations
  • 19 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • HK1 from hepatic stellate cell–derived extracellular vesicles promotes progression of hepatocellular carcinoma
    Qi-tao Chen, Zhi-yuan Zhang, Qiao-ling Huang, Hang-zi Chen, Wen-bin Hong, Tianwei Lin, Wen-xiu Zhao, Xiao-min Wang, Cui-yu Ju, Liu-zheng Wu, Ya-ying Huang, Pei-pei Hou, Wei-jia Wang, Dawang Zhou, Xianming Deng, Qiao Wu
    Nature Metabolism 2022 4 10
  • Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer
    Rui Li, Stephanie L. Ong, Linh M. Tran, Zhe Jing, Bin Liu, Stacy J. Park, Zi Ling Huang, Tonya C. Walser, Eileen L. Heinrich, Gina Lee, Ramin Salehi-Rad, William P. Crosson, Paul C. Pagano, Manash K. Paul, Shili Xu, Harvey Herschman, Kostyantyn Krysan, Steven Dubinett
    Scientific Reports 2020 10 1
  • An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1−HK2+ Multiple Myeloma
    Shili Xu, Tianyuan Zhou, Hanna M. Doh, K Ryan Trinh, Art Catapang, Jason T. Lee, Daniel Braas, Nicholas A. Bayley, Reiko E. Yamada, Alex Vasuthasawat, Joshua P. Sasine, John M. Timmerman, Sarah M. Larson, Youngsoo Kim, A. Robert MacLeod, Sherie L. Morrison, Harvey R. Herschman
    Cancer Research 2019 79 10
  • Degradation of Hexokinase 2 Blocks Glycolysis and Induces GSDME-Dependent Pyroptosis to Amplify Immunogenic Cell Death for Breast Cancer Therapy
    Ruoxi Sang, Renming Fan, Aohua Deng, Jiakui Gou, Ruizhuo Lin, Ting Zhao, Yongrui Hai, Junke Song, Yang Liu, Bing Qi, Guanhua Du, Maosheng Cheng, Gaofei Wei
    Journal of Medicinal Chemistry 2023 66 13
  • Dual Inhibitions on Glucose/Glutamine Metabolisms for Nontoxic Pancreatic Cancer Therapy
    Yingying Xu, Zhiguo Yu, Hao Fu, Yuedong Guo, Ping Hu, Jianlin Shi
    ACS Applied Materials & Interfaces 2022 14 19
  • Single-Cell Sequencing-Enabled Hexokinase 2 Assay for Noninvasive Bladder Cancer Diagnosis and Screening by Detecting Rare Malignant Cells in Urine
    Zhuo Wang, Jie Chen, Liu Yang, Mingzhe Cao, Yanlan Yu, Rulin Zhang, Heng Quan, Qi Jiang, Yingqi Hua, Wei Wei, Peihua Lu, Jun Wu, Qihui Shi
    Analytical Chemistry 2020 92 24
  • A genome‐wide CRISPR activation screen reveals Hexokinase 1 as a critical factor in promoting resistance to multi‐kinase inhibitors in hepatocellular carcinoma cells
    Summer Sofer, Kevin Lamkiewicz, Shir Armoza Eilat, Shirly Partouche, Manja Marz, Neta Moskovits, Salomon M. Stemmer, Amir Shlomai, Ella H. Sklan
    The FASEB Journal 2022 36 3
  • Kaempferol impairs aerobic glycolysis against melanoma metastasis via inhibiting the mitochondrial binding of HK2 and VDAC1
    Xiuqin Zheng, Yanhong Pan, Gejun Yang, Yang Liu, Jueyao Zou, Han Zhao, Gang Yin, Yuanyuan Wu, Xiaoman Li, Zhonghong Wei, Suyun Yu, Yang Zhao, Aiyun Wang, Wenxing Chen, Yin Lu
    European Journal of Pharmacology 2022 931
  • Sirtuin 6 and metabolic genes interplay in Warburg effect in cancers
    Nosayba Al-Azzam
    Journal of Clinical Biochemistry and Nutrition 2020 66 3
  • Aiding Cancer’s “Sweet Tooth”: Role of Hexokinases in Metabolic Reprogramming
    Zeenat Farooq, Hagar Ismail, Sheraz Ahmad Bhat, Brian T. Layden, Md. Wasim Khan
    Life 2023 13 4

Article usage

Article usage: June 2018 to April 2025

AbstractFullPdf
Jun 2018318038
Jul 2018146010
Aug 2018146021
Sep 2018268025
Oct 2018148022
Nov 2018106016
Dec 2018105013
Jan 201960027
Feb 20197312549
Mar 20192341118
Apr 2019981111
May 20198876
Jun 20196635
Jul 201966512
Aug 2019651038
Sep 2019643638
Oct 2019471839
Nov 2019471943
Dec 2019582741
Jan 2020603738
Feb 202025914
Mar 2020441617
Apr 2020432528
May 2020404827
Jun 2020445619
Jul 202045515
Aug 202020107
Sep 2020282713
Oct 2020332628
Nov 2020281419
Dec 2020191724
Jan 2021142514
Feb 2021144831
Mar 202185234
Apr 2021183317
May 2021144222
Jun 2021222719
Jul 2021163531
Aug 2021102617
Sep 2021173318
Oct 2021463856
Nov 202184147
Dec 2021152528
Jan 2022183124
Feb 2022163730
Mar 2022113312
Apr 2022122920
May 2022142636
Jun 202275842
Jul 202211338
Aug 2022102514
Sep 202262720
Oct 2022132822
Nov 2022114229
Dec 20226498
Jan 2023155925
Feb 2023133423
Mar 2023123721
Apr 202392218
May 2023122110
Jun 202361615
Jul 20238169
Aug 202381123
Sep 202341511
Oct 2023154029
Nov 202383416
Dec 2023183316
Jan 2024192211
Feb 20244819
Mar 2024134339
Apr 20241613339
May 202445026
Jun 202454722
Jul 2024103623
Aug 2024253923
Sep 2024122314
Oct 202483233
Nov 2024102926
Dec 2024124423
Jan 2025195127
Feb 2025239641
Mar 2025138832
Apr 2025177980
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 60 (2)
Journal of Nuclear Medicine
Vol. 60, Issue 2
February 1, 2019
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Hexokinase 2 Is Targetable for HK1-Negative, HK2-Positive Tumors from a Wide Variety of Tissues of Origin
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Hexokinase 2 Is Targetable for HK1-Negative, HK2-Positive Tumors from a Wide Variety of Tissues of Origin
Shili Xu, Arthur Catapang, Hanna M. Doh, Nicholas A. Bayley, Jason T. Lee, Daniel Braas, Thomas G. Graeber, Harvey R. Herschman
Journal of Nuclear Medicine Feb 2019, 60 (2) 212-217; DOI: 10.2967/jnumed.118.212365

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Hexokinase 2 Is Targetable for HK1-Negative, HK2-Positive Tumors from a Wide Variety of Tissues of Origin
Shili Xu, Arthur Catapang, Hanna M. Doh, Nicholas A. Bayley, Jason T. Lee, Daniel Braas, Thomas G. Graeber, Harvey R. Herschman
Journal of Nuclear Medicine Feb 2019, 60 (2) 212-217; DOI: 10.2967/jnumed.118.212365
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Fructose Metabolism Contributes to the Warburg effect
  • An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1-HK2+ Multiple Myeloma
  • Google Scholar

More in this TOC Section

Oncology

  • The Evolving Role of FDG-PET/CT in Assessing Primary Cutaneous Lymphoma
  • Molecular imaging of Renal clear cell carcinoma subtypes as metabolic diseases
  • Role of PET/CT in the management of multiple myeloma
Show more Oncology

Basic

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Show more Basic

Similar Articles

Keywords

  • Warburg Effect
  • hexokinase 2
  • hexokinase 1
  • glycolysis
  • targeted therapy
SNMMI

© 2025 SNMMI

Powered by HighWire